Close
  Indian J Med Microbiol
 

Figure 3: MYC amplification, RB1 deletion, APC mutation/deletion, and CDK12 mutation are linked to worse prognosis in our cohort. Survival analysis was performed in Chinese PCa patients treated according to the presence or absence of (a) MYC amplification, (b) RB1 deletion, (c) APC mutation/deletion, and (d) CDK12 mutation. PCa: prostate cancer; MYC: MYC proto-oncogene, bHLH transcription factor; RB1: RB transcriptional corepressor 1; APC: APC regulator of WNT signaling pathway; CDK12: Cyclin-dependent kinase 12.

Figure 3: <i>MYC</i> amplification, <i>RB1</i> deletion, <i>APC</i> mutation/deletion, and <i>CDK12</i> mutation are linked to worse prognosis in our cohort. Survival analysis was performed in Chinese PCa patients treated according to the presence or absence of (a) <i>MYC</i> amplification, (b) <i>RB1</i> deletion, (c) <i>APC</i> mutation/deletion, and (d) <i>CDK12</i> mutation. PCa: prostate cancer; MYC: MYC proto-oncogene, bHLH transcription factor; RB1: RB transcriptional corepressor 1; APC: APC regulator of WNT signaling pathway; CDK12: Cyclin-dependent kinase 12.